VEGFA and glioblastoma: BEV is the first monoclonal antibody approved for marketing, which can competitively bind to vascular endothelial growth factor receptor, block VEGF-mediated angiogenesis, help inhibit angiogenesis of tumor tissue and weaken invasive ability, and has been approved for the first-line treatment of recurrent glioblastoma (28, 29).